Luminex (LMNX) versus Dextera Surgical (NASDAQ:DXTR) Head-To-Head Analysis

Luminex (NASDAQ: LMNX) and Dextera Surgical (NASDAQ:DXTR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Luminex and Dextera Surgical, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Luminex 1 3 1 0 2.00
Dextera Surgical 0 0 2 0 3.00

Luminex currently has a consensus price target of $20.50, suggesting a potential downside of 1.11%. Dextera Surgical has a consensus price target of $0.75, suggesting a potential upside of 1,775.00%. Given Dextera Surgical’s stronger consensus rating and higher possible upside, analysts plainly believe Dextera Surgical is more favorable than Luminex.


Luminex pays an annual dividend of $0.24 per share and has a dividend yield of 1.2%. Dextera Surgical does not pay a dividend. Luminex pays out 35.8% of its earnings in the form of a dividend.

Valuation & Earnings

This table compares Luminex and Dextera Surgical’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Luminex $270.64 million 3.37 $13.81 million $0.67 30.94
Dextera Surgical $3.42 million 0.56 -$17.22 million ($1.77) -0.02

Luminex has higher revenue and earnings than Dextera Surgical. Dextera Surgical is trading at a lower price-to-earnings ratio than Luminex, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Luminex has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, Dextera Surgical has a beta of -1.35, suggesting that its stock price is 235% less volatile than the S&P 500.


This table compares Luminex and Dextera Surgical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Luminex 9.52% 6.01% 5.47%
Dextera Surgical -402.96% N/A -195.83%

Institutional and Insider Ownership

79.2% of Luminex shares are held by institutional investors. Comparatively, 4.5% of Dextera Surgical shares are held by institutional investors. 6.9% of Luminex shares are held by insiders. Comparatively, 10.4% of Dextera Surgical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.


Luminex beats Dextera Surgical on 11 of the 16 factors compared between the two stocks.

About Luminex

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments. The Company has a range of instruments using its xMAP technology, which includes its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to a range of testing laboratories.

About Dextera Surgical

Dextera Surgical Inc., formerly Cardica, Inc., designs and manufactures stapling devices that enable the advancement of minimally invasive surgical procedures. The Company is engaged in commercializing and developing its MicroCutter 5/80 stapler based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons. Its MicroCutter 5/80 is a commercially available cartridge-based microcutter device with approximately five millimeter shaft diameter, over 80 degrees of articulation, and an approximately 30 millimeter staple line cleared for specified indications for use in the United States, and in the European Union (EU) for a range of indications for use. It designs, manufactures and markets automated anastomotic systems used by surgeons to perform anastomoses during on- or off-pump coronary artery bypass graft procedures and these products include the C-Port xA system, the C-Port Flex A system and the PAS-Port Proximal Anastomosis System.

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with's FREE daily email newsletter.

Leave a Reply